BioSpace News Archive

The toxicology testing services market is expected to drive robust growth in the near future as various drugs are on track to be legalized for both medicinal and recreational purposes.

Transparency Market Research titled “Thrombosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Transparency Market Research has published a new report titled, “Cardiac Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The demand within the global DNA/gene microarray market is expected to rise alongside advancements in genetic studies.

Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint

PNH is a rare but severe and usually life-long blood disease in which the blood cells are fragile and easily destroyed by a part of the patient’s own immune system, called complement.

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia and severe sickle cell disease, and highlighted recent progress in the CTX001 development program.

Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib

Preliminary Results from Fully Enrolled ALX148 Plus Rituximab Combination Cohort Presented at the 25th Congress of the European Hematology Association

Lonca demonstrated an overall response rate of 48.3% and complete response rate of 24.1% in the pivotal Phase 2 single-agent trial